Dermatologists know how to perform hidradenitis suppurativa deroofing – they just don’t know that they know how! That’s according to Dr. Steven Daveluy, professor and program director at Wayne State Dermatology. In an interview with Next Steps in Derm, in partnership with the ODAC Dermatology Conference, Dr. Daveluy shares his encouragement for dermatologists to try deroofing even if they weren’t formally trained on the procedure. Learn in what patient population dermatologists should consider deroofing and other hidradenitis suppurativa procedures. Hear Dr. Daveluy’s steps for deroofing. Plus find out why Dr. Daveluy says hidradenitis suppurativa requires a multifaceted treatment strategy.
Further Reading
If you want to read more about hidradenitis suppurativa, check out the following articles published in the Journal of Drugs in Dermatology:
The Efficacy of Intense Pulsed Light and Laser Hair Removal in Hidradenitis Suppurativa Treatment
ABSTRACT
Background: Hidradenitis suppurativa (HS) is a multifactorial disease that presents with chronic cycles of inflammation, healing, and scarring and that elicits a profoundly negative impact on patient quality of life regarding self-image, fear of stigmatization, and social isolation. Patients commonly develop painful, odorous abscesses that evolve into draining sinus tracts and disfiguring scarring.
Objective: While systemic medications and surgical therapies are often effective in reducing active lesion activity and inflammation, these therapies sometimes only provide modest success in the prevention of future recurrences and disease progression, warranting adjunctive therapies such as laser and light-based therapies. Herein, this systematic review has been conducted to assess the current level of evidence supporting intense pulsed light (IPL) and laser treatment for HS, with a focus on a decrease in the number of lesions with associated HS flares.
Methods: GRADE assessments were performed using PubMed and Scopus. Of 428 studies identified, 10 studies (n= 235) evaluated IPL or laser hair removal treatment and their effectiveness in reducing HS flares.
Results: Significant reductions in the overall count of inflammatory lesions were observed in all studies, with percentages ranging from 50% to 75%, and in some cases, achieving complete resolution. However, durations of disease remission varied.
Conclusion: These results provide a moderate level of evidence supporting the effectiveness of IPL and laser hair removal as adjunctive therapy in the treatment of HS; however, further long-term studies are required to provide future guidance on the most effective treatment duration and intervals for sustaining disease clearance.
A Review of the Current Landscape of Hidradenitis Suppurativa Treatment Development
ABSTRACT
Background: Hidradenitis suppurativa (HS) is a chronic inflammatory skin condition characterized by recurrent nodules and abscesses leading to subsequent scarring and tunnel formation. Despite being a fairly common disease with a significant impact on quality of life, only one drug, adalimumab, is currently US Food and Drug Administration (FDA)-approved for treating HS. However, there are many clinical trials underway to address this gap in care for patients with HS.
Methods: All clinical trials related to HS as of 10/03/2022 were reviewed via clinicaltrials.gov. Studies on topical or systemic medical therapies were included and available results reported if they were ongoing or completed within 6 months prior to the search.
Results: Over 30 drugs with at least 20 different mechanisms of action are currently in development for the treatment of HS. While many of these are in phase 2 trials, several are undergoing phase 3 trials and will likely become viable treatment options in the next 5 years.
Conclusions: Following years of limited treatment options for HS, drug development has accelerated significantly, forecasting more treatment possibilities and better disease control for many patients.
Did you enjoy this video interview? Find more here.
